Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens

AIDS

Volumn 13, Issue 10, 1999, Pages 1207-1212

  Hall, Christopher S ^a   Raines, Charles P ^a   Barnett, Scott H ^a   Moore, Richard D ^a   Gallant, Joel E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Combination therapy; Protease inhibitors

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; NELFINAVIR; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SALVAGE THERAPY; SAQUINAVIR; TREATMENT FAILURE; VIRAL LOAD;

EID: 0032792127     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907090-00009     Document Type: Article

References (13)

1. 1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
2. 2. Cameron DW, Japour A, Mellors J, et al. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor-naive patients in year 2 of follow-up. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 388].
3. 3. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
4. 4. Molla A, Korneyeva M, Gao Q., et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
5. 5. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999, 13:F23-F28.
6. 6. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic eveidence of indinavir or ritonavir failure. AIDS 1998, 12:F97-F102.
7. 7. Puig T, Bonjoch A, Ruiz L, et al. Usefulness of ritonavir and saquinavir combination therapy in HIV advanced patients failing on indinavir. 37th ICAAC. Toronto, October 1997 [abstract 1-201].
8. 8. Lallemand F, Adda N, Schneider V, et al. Prospective follow-up of 67 indinavir-experienced HIV/AIDS patients treated with ritonavir/saquinavir combination. 38th ICAAC. San Diego, September 1998 [abstract 1-194].
9. 9. Hammer S, Squíres K, Degruttola V, et al. Randomized trial of abacavir (ABC) and nelfinavir (NFV) in combination with efavirenz (EFV) and adefovir dipivoxil (ADV) as salvage therapy in patients with virologic failure receiving indinavir. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 490].
10. 10. Deeks SG. Twenty-week HIV RNA response and correlation with baseline phenotypic drug susceptibility during treatment with a novel quadruple salvage regimen after failure of indinavir combination therapy. 12th World AIDS Conference. Geneva, June 1998 [abstract 22490].
11. 11. Havlir D, Hellmann N, Petropoulos C, et al. Viral rebound in the presence of indinavir without protease inhibitor resistance. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract LB12].
12. 12. Descamps D, Peytavin G, Calvez V, et al. Virologic failure, resistance, and plasma drug measurements in induction maintenance therapy trial (ANRS 072, Trilege). Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 493].
13. 13. Holder DJ, Condra JH, Schleif WA, et al. Virologic failure during combination therapy with Crixivan and RT inhibitors is often associated with expression of resistance-associated mutations in RT only. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 492].